المؤلفون: Camacho-Arteaga LF; Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, Spain; Clinical Pharmacology Department, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain; Clinical Pharmacology, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Spain., Gardarsdottir H; Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, the Netherland; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, the Netherland; Department of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland., Ibañez L; Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, Spain; Clinical Pharmacology Department, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain; Clinical Pharmacology, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Spain; Catalan Institute of Pharmacology Foundation, Spain., Souverein PC; Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, the Netherland., van Dijk L; Nivel, Netherlands Institute for Health Services Research, Utrecht, the Netherland., Hek K; Nivel, Netherlands Institute for Health Services Research, Utrecht, the Netherland; Department of PharmacoTherapy, Epidemiology and Economics (PTEE), Faculty of Science and Engineering, University of Groningen, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands., Vidal X; Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, Spain; Clinical Pharmacology Department, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain; Clinical Pharmacology, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Spain; Catalan Institute of Pharmacology Foundation, Spain., Ballarín E; Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, Spain; Clinical Pharmacology, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Spain; Catalan Institute of Pharmacology Foundation, Spain., Sabaté M; Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, Spain; Clinical Pharmacology Department, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain; Clinical Pharmacology, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Spain; Catalan Institute of Pharmacology Foundation, Spain. Electronic address: mosabate@vhebron.net.

المصدر: Journal of affective disorders [J Affect Disord] 2022 Apr 15; Vol. 303, pp. 131-137. Date of Electronic Publication: 2022 Feb 05.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7906073 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-2517 (Electronic) Linking ISSN: 01650327 NLM ISO Abbreviation: J Affect Disord Subsets: MEDLINE

مواضيع طبية MeSH: Antidepressive Agents*/therapeutic use , Sleep Wake Disorders*/drug therapy, Aged ; Anxiety ; Female ; Humans ; Longitudinal Studies ; Selective Serotonin Reuptake Inhibitors/therapeutic use